Welcome to our dedicated page for Haleon news (Ticker: HLN), a resource for investors and traders seeking the latest updates and insights on Haleon stock.
Haleon plc (HLN) generates a steady stream of news as a global consumer health company with a portfolio that spans Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. This news page aggregates coverage of Haleon’s brand activity, partnerships, research collaborations and corporate announcements, giving readers a single place to review the latest developments affecting the company and its well-known brands such as Advil, Centrum, Sensodyne, Voltaren and TUMS.
Recent news releases highlight how Haleon activates its brands through consumer campaigns and partnerships. TUMS has featured in promotions tied to major football events, including sweepstakes and themed games with partners like DraftKings and creator Eric Decker (Airrack), emphasising fast-acting relief from occasional heartburn during food-focused occasions. Other updates showcase product and packaging initiatives, such as the use of bio-based materials in the nasal spray pump used with Haleon’s Otrivin brand through a collaboration with Aptar Pharma.
Haleon’s news flow also reflects its focus on science and research. Announcements include the groundbreaking of a Global Oral Health Innovation Centre in Weybridge to act as an R&D hub for oral health, participation as the central industry partner in a UK-wide doctoral training programme on oral health, and a collaboration with Brightseed to use the Forager AI platform for discovering plant-based small molecules with potential health benefits.
Corporate and strategic updates appear alongside brand stories, including changes to Haleon’s operating model, leadership appointments and digital initiatives such as adopting Salesforce Life Sciences Cloud for Customer Engagement. Investors and observers can use this page to follow how Haleon’s category strategy, research focus and brand activations are reflected in its public announcements over time.
Haleon has appointed Joe Sta-Romana as Chief Customer Officer (CCO) for its US business, effective December 1, 2024. Sta-Romana, who previously led Unilever's Walmart business and has over 20 years of experience in the FMCG sector, will lead the organization's customer strategy and drive growth in the US market. In his new role, he will focus on implementing customer-focused strategies, improving data analytics, enhancing digital solutions, and building stronger partnerships with key retailers. The appointment aims to strengthen Haleon's position in delivering better everyday health solutions through improved customer relationships.
Haleon has launched Eroxon®, the first FDA-cleared over-the-counter gel for erectile dysfunction (ED) in the U.S. Available for pre-order on Amazon and in major retailers by October 2024, Eroxon® is clinically proven to help men achieve erections within 10 minutes. This fast-acting treatment addresses a significant unmet need, as existing prescription solutions can take up to an hour to work.
Clinical studies demonstrate Eroxon®'s safety and efficacy for men with ED. The gel stimulates nerve endings in the penis to aid in achieving and maintaining erections. Haleon aims to make this accessible treatment available to millions of American men affected by ED, emphasizing the importance of sexual health in overall wellness.
Dr. Reddy's Laboratories announced the acquisition of Haleon's Nicotinell and related NRT brands for GBP 500 million. The acquisition includes Nicotinell's global portfolio, comprising Nicabate, Thrive, and Habitrol, across Europe, Asia, and Latin America. The deal features an upfront payment of GBP 458 million and performance-based payments of up to GBP 42 million. Nicotinell, the second-largest NRT brand globally, generated GBP 217 million in revenue in CY'23. Dr. Reddy's aims to expand its OTC business and strengthen its global consumer healthcare presence. The transaction is expected to close in early Q4 2024.
Yellow Wood Partners, a Boston-based private equity firm, announced that its portfolio company, Suave Brands Company, has completed the acquisition of the ChapStick brand from Haleon (LSE / NYSE: HLN). This acquisition also makes Haleon a shareholder in Suave Brands Company. The CEO of Suave Brands, Daniel Alter, stated that the addition of ChapStick fits their growth strategy and enhances their position in the North American beauty and personal care market. Suave Brands, known for offering affordable personal care products, now boasts annual retail sales of around $800 million. Yellow Wood Partners highlighted the strategic value of combining ChapStick with Suave, expanding product capabilities, and leveraging Suave's market presence. The acquisition aligns with Yellow Wood Partners' approach to value-creating acquisitions and organic growth strategies.
FAQ
What is the current stock price of Haleon (HLN)?
What is the market cap of Haleon (HLN)?
